To date, the NCCN guidelines have recommended a two-stage risk assessment, 1st step: further genetic risk evaluation, and 2nd step: testing criteria, based on clinical findings of breast and ovarian cancer, as a comprehensive approach to genetic testing in subjects suspected of harboring BRCA1/2 mutations. The gene discussed is BRCA1; the disease is ovarian cancer.